TY - JOUR
T1 - It is time for a new comprehensive medication review quality measure
AU - Castora-Binkley, Melissa
AU - Hines, Lisa
AU - Vaffis, Shannon
AU - Dhatt, Harman
AU - Anderson, Elizabeth
AU - Le, Darlena
AU - Black, Heather
AU - Campbell, Patrick J.
AU - Kolobova, Irina
AU - Nelson, Mel
AU - Axon, David R.
AU - Warholak, Terri
N1 - Funding Information:
zona. Dr Dhatt is an employee of Janssen and discloses this was work was completed previously during her employment at the University of Arizona. Dr Anderson is an employee of The Freedom Fund and discloses this was work was completed previously during her employment at the University of Arizona. Dr Black is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Dr Campbell received funding from Pharmacy Quality Alliance, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and SinfoniaRx and discloses this work was completed previously during his employment at the University of Arizona. Dr Kolobova is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Dr Hines is an employee of Pharmacy Quality Alliance. Dr Castora-Binkley is an employee of Pharmacy Quality Alliance. Dr Nelson is an employee of Pharmacy Quality Alliance. Dr Axon received funding from Pharmacy Quality Alliance, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and SinfoniaRx. Dr Warholak received funding from Pharmacy Quality Alliance,
Publisher Copyright:
Copyright©2023, Academy of Managed Care Pharmacy. All rights reserved.
PY - 2023/6
Y1 - 2023/6
N2 - Medication therapy management (MTM) services include comprehensive medication reviews (CMRs), which have been completed with millions of patients since their inception in the United States. The current MTM quality measure focuses on whether CMRs were completed (ie, the CMR completion rate). However, this process measure does not assess quality of care, or patient-reported or other outcomes of CMRs, and, therefore, does not reward MTM providers for improving health outcomes. In this viewpoint article, we present 3 reasons that shape our argument for new MTM quality measures and offer recommendations on next steps to achieve this.
AB - Medication therapy management (MTM) services include comprehensive medication reviews (CMRs), which have been completed with millions of patients since their inception in the United States. The current MTM quality measure focuses on whether CMRs were completed (ie, the CMR completion rate). However, this process measure does not assess quality of care, or patient-reported or other outcomes of CMRs, and, therefore, does not reward MTM providers for improving health outcomes. In this viewpoint article, we present 3 reasons that shape our argument for new MTM quality measures and offer recommendations on next steps to achieve this.
UR - http://www.scopus.com/inward/record.url?scp=85160972288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160972288&partnerID=8YFLogxK
U2 - 10.18553/jmcp.2023.29.6.680
DO - 10.18553/jmcp.2023.29.6.680
M3 - Article
C2 - 37276042
AN - SCOPUS:85160972288
SN - 2376-0540
VL - 29
SP - 680
EP - 684
JO - Journal of Managed Care and Specialty Pharmacy
JF - Journal of Managed Care and Specialty Pharmacy
IS - 6
ER -